Piper Sandler Initiates Coverage On Capricor Therapeutics with Overweight Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Capricor Therapeutics with an Overweight rating and set a price target of $35.
October 21, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Capricor Therapeutics with an Overweight rating and a price target of $35, indicating a positive outlook.
The initiation of coverage with an Overweight rating and a price target of $35 by Piper Sandler suggests a positive outlook for Capricor Therapeutics. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100